TRK-250
As of the edition of 20 October 2026, TRK-250 is a drug known only by a code name: of no established status; acts on TGFB1.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Status not established
- Kind
- Code name only
- Registered trials
- 1, 0 stopped early
- Disease areas
- Lungs and airways
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| TGFB1 | Transforming growth factor beta-1 proprotein [Cleaved into: Latency-associated peptide | P01137 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 1 | 1 | 0 | 0 |
| All trials | 1 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Toray Industries | Lead sponsor of trials | 2018 to now |